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Abstract
The objective was to estimate chronic kidney disease (CKD) incidence rates from preva-
lence and mortality data, and compare the estimates with observed (true) incidence rates in
a well-characterized population with diabetes. Pima Indians aged 20 years and older with
type 2 diabetes were followed from 1982 through 2007. CKD was defined by estimated GFR
(eGFR) <60 ml/min/1.72 m2 or albumin-to-creatinine ratio (ACR)30 mg/g. True CKD inci-
dence and mortality rates were computed for the whole study period, and prevalence for the
intervals 1982–1994 and 1995–2007. Estimated age-sex stratified CKD incidence rates
were computed using illness-death models of the observed prevalences, and of the whole-
period mortality rate ratio of CKD to non-CKD persons. Among 1201 participants, 616 inci-
dent events of CKD occurred during a median follow-up of 5.6 years. Observed CKD preva-
lence was 56.9% (95%CI 53.7–60.0) and 48.0% (95%CI 45.2–50.8) in women; 54.0% (95%
CI 49.9–58.1) and 49.6% (95%CI 46.0–53.3) in men, across the two periods. Mortality rate
was 2.5 (95%CI 1.9–3.3) times as high in women with CKD and 1.6 (95%CI 1.3–2.1) times
as high in men with CKD, compared to women or men without CKD. In women, estimated
CKD incidence increased linearly from 25.6 (95%CI 4.2–53.0) to 128.6 (95%CI 77.1–196.6)
with each 5-year age group up to 69 years, and to 99.8 (95%CI 38.7–204.7) at age70. In
men, estimated CKD incidence increased form 28.5 (95%CI 3.8–71.2) at age 20–24 years
to 118.7 (95%CI 23.6–336.7) at age70. Age-sex-stratified estimated incidence reflected
the magnitude and directional trend of the true incidence and were similar to the true inci-
dence rates (p>0.05 for difference) except for age 20–24 in women (p = 0.008) and age 25–
29 in men (p = 0.002). In conclusion, the estimated and observed incidence rates of CKD
agree well over 25 years of observation in this well characterized population with type 2
diabetes.
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Introduction
Chronic kidney disease (CKD) affects 39.2% of adults with diabetes in the United States [1].
When adjusted for demographic characteristics of the population, the prevalence of CKD in
2007–2012 was slightly but non-significantly lower than in 1988–1994, even though the death
rate remained largely stable in the general population and tended to decline among persons
with diabetes over the same time period [2]. This observation suggests the incidence of CKD
due to diabetes may have declined over this period. Yet, national estimates of CKD incidence
are essentially unknown. Although the National Health and Nutrition Examination Survey
cycles allow us to estimate national prevalence of CKD and overall mortality rates with reason-
able precision, the serial cross-sectional design precludes computation of true incidence rates
of CKD. Obtaining true incidence estimates would require regular albuminuria and kidney
function testing over a long period of time, which is expensive and logistically difficult to per-
form in the absence of population registries. It is possible, however, to overcome these chal-
lenges by applying the illness-death model–a well-described [3,4] mathematical relationship
between incidence, prevalence and mortality–to observational epidemiologic data.
In this study, we use observations from a well-characterized population with type 2 diabetes
to estimate CKD incidence rates from observed prevalence and mortality data, and then com-
pare these estimates with true CKD incidence rates in this population. We demonstrate that
estimating CKD incidence using the illness-death model represents a reliable method for esti-
mating incidence rates from cross-sectional studies.
Materials and methods
Study population and design
A longitudinal study of diabetes and related conditions was conducted in the Gila River Indian
Community in southern Arizona from 1965 through 2007 [5]. Participants predominantly of
Pima or Tohono O’odham heritage were invited to participate in biennial research examina-
tions. Biochemical tests and an oral glucose tolerance test were administered at these research
examinations, and detailed medical and familial histories were recorded. Measurements of
urine albumin were conducted in all examinations performed on or after July 1, 1982. For the
present study, we selected participants who had type 2 diabetes from this longitudinal popula-
tion-based study and who were 20 years and older at the time of their first examination after
July 1, 1982. Diabetes in the Pima Indians is entirely type 2 diabetes mellitus, including in chil-
dren and adolescents, and it is characterized by the lack of insulin dependence [6], absent or
low levels of islet cell and glutamic acid decarboxylase antibodies [7, 8], and absence of strong
linkage or association with maturity-onset diabetes of youth loci [9–11]. All participants were
then followed until death or their last research examination before the end of the study period,
December 31, 2007, whichever came first. Those with missing serum creatinine measures were
excluded from analysis (representing 2.09% of the initial cohort).
Diabetes was diagnosed by a 2-hour post-load plasma glucose level11.1 mmol/L (200 mg/
dL). The date of diabetes diagnosis was determined from these research examinations or from
review of clinical records if diabetes was diagnosed during routine medical care. Serum creati-
nine was measured by a modified Jaffé reaction with calibration traceable to an isotope-dilu-
tion mass spectrometry measurement procedure [12]. Albumin and creatinine concentrations
were measured in urine specimens collected at the end of the glucose-tolerance test. Urinary
albumin was measured by nephelometric immunoassay and concentrations below the thresh-
old detected by the assay (6.8 mg/L) were set to this value in the analyses. Elevated albuminuria
was defined by an ACR30 mg albumin/g creatinine. The estimated glomerular filtration rate
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(eGFR) was computed by the CKD-EPI equation [13]. CKD was defined by eGFR<60 ml/
min/1.72 m2 or ACR30 mg/g.
The study was approved by the Review Board of the National Institute of Diabetes and
Digestive and Kidney Diseases. Each participant gave written informed consent.
Statistical analysis
Observed (true) CKD incidence rate, prevalence, and mortality. Observed incidence of
CKD was calculated for the whole study period as the number of new CKD events per 1,000
person-years at risk. Follow-up extended from the date of the first diabetic research examina-
tion after the age of 20 years without CKD to first date with CKD or, in those who did not
develop CKD, to the date of the last research examination within the study period. The age-
and sex-specific remission rates r were computed among those with pre-dialysis CKD as the
count of transitions to the "non-CKD" state (numerator) divided by the person-time at risk for
remission (denominator); only the first remission event was counted. Observed prevalence of
CKD was computed for the calendar intervals 1982–1994 and 1995–2007 using data from the
research examination closest to the midpoint of each period. Observed death rates were com-
puted for the whole study period as the number of subjects without or with CKD who died of
any cause per 1,000 person-years of follow-up. The period at risk for the without CKD death
rate began at the first diabetic examination and ended at the date of death, onset of CKD, or
December 31, 2007, whichever came first. The period at risk for those with CKD death rate
began at the first diabetic examination with CKD and ended at the date of death or December
31, 2007, whichever came first.
Estimated CKD incidence rate. To estimate incidence of CKD we used the illness-death
model shown in Fig 1 [14]. Living persons with diabetes aged a at calendar time t are either
without CKD or with CKD. Persons may change status according to the transition rates i, r,
m0, m1, where i represents CKD incidence, r is the CKD remission rate, m0 the death rate
among persons with diabetes without CKD, and m1 the death rate among persons with both
diabetes and CKD.
Fig 1. Illness-death model with transition rates (i, r, m0, m1). CKD, chronic kidney disease; T2DM, type 2 diabetes mellitus.
doi:10.1371/journal.pone.0171027.g001
Chronic kidney disease incidence from prevalence and mortality data
PLOS ONE | DOI:10.1371/journal.pone.0171027 February 6, 2017 3 / 11





þ p m1   m0ð Þ ð1Þ
Where @p represents change of prevalence in time (partial derivative), rp is remission rate,
m0 death rate without CKD, m1 the death rate with CKD, and p is the prevalence in the middle
(t), between the first point in time (t1) and the second (t2), i.e.
t ¼ 0:5 ðt1 þ t2Þ
p(t, a) is estimated from the two surveyed prevalences:
p t; að Þ ¼
h2
h1 þ h2
p t1; a   h1ð Þ þ
h1
h1 þ h2
pk t2; aþ h2ð Þ
h1 ¼ t
   t1
h2 ¼ t2   t

a = age [15].
We then compared the incidence rate estimated via Eq (1) with the observed incidence
rate. The 95% confidence intervals (CIs) for the estimated incidence rates were obtained by a
Monte-Carlo simulation (1000 replications). For more details about the method see Brinks
and Landwehr [14]. Pointwise differences between the true and estimated incidence values
were evaluated by computing the 95% CI of the difference between the true and estimated inci-
dence. If the calculated interval includes zero, there is no evidence for a difference between the
true and estimated incidence rates.
Baseline clinical and demographic features of the study population are presented as median
and interquartile range (IQR). Body mass index (BMI) was defined as weight divided by the
square of height (kg/m2). Mean arterial pressure (MAP) was calculated as 2/3 diastolic arterial
pressure + 1/3 systolic arterial pressure. A χ2 tests for general association were used to examine
relationships between time period, hypoglycemic and antihypertensive treatment; median val-
ues were compared by the Kruskal–Wallis test.
Results
Characteristics of the study population listed in Table 1 are presented for the two time periods
for which CKD prevalence was computed. In the second period, the study population was
younger, with higher BMI and eGFR, and lower fasting glucose levels, ACR, and MAP. Usage
of anti-hypertensive and hypoglycemic treatments improved over time.
Among 1201 participants (783 women, 418 men) with type 2 diabetes and without CKD at
baseline, 616 (407 women, 209 men) incident events of CKD occurred during a median of 5.6
years of follow-up (IQR 2.9 to 9.9 years); 19 of these represented incident dialysis cases. The
observed age- and sex-stratified incidence rates of CKD are shown in Table 2. Overall, observed
CKD incidence was 76.5 events/1,000 person-years (95% CI 70.6–82.8), and was similar in
women (74.9 events/1,000 person-years, 95% CI 67.8–82.6) and men (79.7 events/1,000 person-
years, 95% CI 69.3–91.3).
Among those with pre-dialysis CKD, 341 (249 women, 92 men) experienced remission of
CKD during a median follow-up of 4.8 years (IQR 2.3 to 9.6 years); all except three of these
remissions were due to reduction of ACR from30 mg/g to<30 mg/g. The overall CKD
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remission rate was 50.2 events/1,000 person-years (95% CI 45.0–55.8); CKD remission rate
was 52.9 events/1,000 person-years in women (95% CI 46.6–60.0), and 44.0 events/1,000 per-
son-years in men (95% CI 35.5–54.0) (S1 Table). In the present study, when defining CKD by
an eGFR<60 ml/min/1.73 m2, the overall incidence of CKD was 25.4 events/1,000 person-
years (95% CI 21.3–30.1) in men and 21.9 events/1,000 person-years (95% CI 19.3–24.8) in
women.
Observed CKD prevalence estimates for the first and second periods are shown in S2 Table,
stratified by age and sex. Overall, observed prevalence declined from 55.7% (95% CI 53.3–
58.3) in 1982–1994 to 48.6% (95% CI 46.4–50.8) in 1995–2007 (p<0.001). In women, CKD
prevalence declined from 56.9% (95% CI 53.7–60.0) to 48.0% (95% CI 45.2–50.8) (p<0.001).
By contrast, the CKD prevalence remained stable in men at 54.0% (95% CI 49.9–58.1) and
49.6% (95% CI 46.0–53.3) (p = 0.12).
The observed age- and sex-stratified death rates, overall and by presence of CKD, are shown
in S3 Table. Observed death rate was 2.5 (95% CI 1.9–3.3) times as high in women with CKD
and 1.6 (95% CI 1.3–2.1) times as high in men with CKD, compared to women or men without
CKD.
Age-sex stratified observed (i.e., true) and estimated incidence rates are shown in Fig 2 and
Table 2. The magnitude and directional trend of the true incidence with increasing age is
reflected in the estimated incidence. The agreement between the true and estimated incidence
is very close (p>0.05) in women of all age groups except 20–24 years (p = 0.008). The agree-
ment in men also appears similar, except for age group 25–29 years (p = 0.002) (Table 2).
Discussion
The estimated incidence rate of CKD based on the illness-death model agreed well with the
observed incidence of CKD in this well characterized population with type 2 diabetes. Esti-
mated incidence rates, computed from observed prevalence and mortality data, reproduced
the true incidence rates particularly well in women, largely due to a greater number of women
than men in each 5-year age group.
Why is it important to know incidence rate of CKD? Although the term ‘epidemic’ has
been used in recent years to describe the increasing prevalence of CKD, a true epidemic would
Table 1. Characteristics of the study population with type 2 diabetes for the prevalence periods.
Prevalence Period
1982–1994 1995–2007 p
n (Male/Female) 1502 (565/937) 1957 (711/1246)
Age (years) 46 (36–57) 44 (36–54) 0.001
Diabetes duration (years) 6.6 (0–14.9) 6.5 (0.7–14.5) 0.35
A1c (%) 8.5 (6.3–10.5) 8.0 (6.4–10.3) 0.36
Fasting glucose (mg/dL) 194 (129–258) 154 (117–230) <0.001
BMI (kg/m2) 32.6 (28.2–38.1) 35.3 (30.8–41.4) <0.001
MAP (mmHg) 94.0 (86.0–103.3) 91.3 (83.3–100.0) <0.001
eGFR (ml/min/1.73 m2) 110 (97–122) 113 (100–123) <0.001
ACR (mg/g) 29.3 (13.1–155.9) 23.5 (10.3–98.2) <0.001
Hypoglycemic treatment (%) 42 50 <0.001
Anti-hypertensive treatment (%) 21 46 <0.001
Values are shown as median (interquartile range). A1c, haemoglobin A1c; ACR, albumin/creatinine ratio;
BMI, body mass index; eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure.
doi:10.1371/journal.pone.0171027.t001
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require an increasing incidence of the disease. Unlike prevalence, CKD incidence rate is specif-
ically reflecting exposure to particular risk factors and therefore its measure helps characterize
factors contributing to disease onset and progression, estimate how changes in these exposures
Table 2. Age- and sex-specific observed (true) and estimated incidence rate of chronic kidney disease in the cohort with type 2 diabetes during
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impact development of disease over time, and evaluate the effectiveness of prevention strate-
gies and health interventions. Knowing how much of the prevalence is due to incidence of a
Fig 2. Age- stratified observed and estimated incidence rates of CKD in women (above) and men (below)
during the period 1982–2007. The asterisk (*) indicates significant difference between true and estimated CKD
incidence.
doi:10.1371/journal.pone.0171027.g002
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disease over time has therefore important implications for the allocation of limited public and
healthcare resources for the prevention and treatment of kidney diseases.
Except for reports on the incidence of end-stage renal disease [16, 17], true incidence (i.e.,
incidence density rate) of diabetic CKD is seldom available in population based studies, in part
because this measure of disease occurrence requires a cohort large enough or with consider-
able follow-up time to analyze the progression to CKD among people at various levels of risk.
Furthermore, systematic information on both albuminuria and eGFR is needed to define inci-
dent events, and even when prevalence data are available, mortality in both those with and
without the disease is necessary to compute CKD incidence rate.
A study among 14,873 participants in the community-based, multicenter, biracial Athero-
sclerosis Risk in Communities Study (ARIC), used different case definitions to estimate CKD
incidence during nine years of follow-up [18]. Because the study had no information on base-
line albuminuria, incident events largely reflected risk of advanced kidney disease, defined by
increase in serum creatinine, decrease in eGFR, International Classification of Diseases codes
for hospitalizations or mortality involving a kidney diagnosis. Among those with diabetes,
CKD incidence varied between 18.9 events /1,000 person-years (95% CI 16.4–21.8) and 6.3
events/1,000 person-years (95% CI 5.1–7.7), contingent on case definition. In a prospective
cohort study of 3,443 outpatients with type 2 diabetes, sampled from 56 primary health care
centers in Spain, the incidence density of stages 3–5 CKD, defined by an eGFR<60 ml/min/
1.73 m2, was 24.8 events per 1000 person-years (95% CI 21.9–27.9) between 2007–2012 [19].
The incidence rate was found to be lower among patients with less than 10 years duration of
diabetes (20.3 events per 1000 person-years, 95% CI 17.3–23.8) than in those with longer dura-
tion of diabetes (35.4 events per 1000 person-years, 95% CI 29.2–42.5). In a community-based
cohort of 3,313 Iranian adults, the incidence rate of eGFR <60 ml/min/1.73 m2 was 21.5 (95%
CI 19.9–23.1) per 1,000 person-years during a mean follow-up of 9.9 years; incidence rates
among women and men were 28.5 (95% CI 26.2–31.1) and 13.3 (95% CI 11.6–15.2), respec-
tively [20]. The cohort, however, included a small proportion of people with diabetes—about
2%.
Accounting for the remission rate of CKD is important when estimating CKD incidence
by the illness-death model. A substantial proportion of persons with moderate albuminuria
regress to normoalbuminuria, either spontaneously or as a result of treatment, indicating a mea-
sure of reversibility of initial kidney injury rather than inevitable progression to ESRD. Gener-
ally, the proportion of persons with type 2 diabetes who regress from moderate to normoal-
buminuria is 30%-54%, while the frequency of progression to overt proteinuria is 12%-36%
[21–23]. In a previous study among Pima Indians with type 2 diabetes we found that 23% expe-
rienced progression and 8% experienced regression of ACR between two consecutive measure-
ments taken within a 6-year period [23]. In the present study the remission rate of CKD was
almost entirely due to ACR remission to normal values and to a lesser extent to eGFR surge
above 60 ml/min/1.73 m2. Thus, accounting for the remission rate in the differential equations
will substantially improve the incidence model when all stages of CKD are considered, but may
not have any impact on the modelling when CKD is defined by GFR<60 ml/min/1.73 m2 only.
The applicability of the illness-death model for extracting incidence density estimates from
prevalence and mortality data has been demonstrated previously for chronic diseases such as
renal replacement therapy [24], dementia [25], and diabetes [26]. The present study adds to
previous information by replicating the model in a non-Caucasian population and accounting
for the remission rate of a chronic disease.
The strength of the study derives from including a population in whom type 2 diabetes and
CKD are known with greater accuracy than in other studies because of systematic periodic
testing as part of the longitudinal follow-up. The study limitations relate to 1) the inclusion of
Chronic kidney disease incidence from prevalence and mortality data
PLOS ONE | DOI:10.1371/journal.pone.0171027 February 6, 2017 8 / 11
a homogenous cohort of Pima Indians, however, these results are intended to add to previous
ones conducted in predominantly Caucasian populations; 2) it is the first time that the method
is applied to such a long period, covering 25 years of data. Many changes might have happened
during that time, including changes in risk factors, in treatment and mortality, all of which
might not be captured in two cross-sections. Even so, the magnitudes of the estimated and
observed incidences are similar. Another important limitation is our method of determining if
the true and estimated incidences are the same. We tested the null hypothesis that the true and
estimated incidences are the same. In effect, this says that they will be declared the same unless
the data provide strong evidence that they are different. This could be addressed in some
future study by the use of equivalence testing, instead of difference testing.
In conclusion, over 25 years of observation, the estimated incidence rate of CKD based on
the illness-death model agreed well with the observed (true) incidence of CKD in Pima Indians
with type 2 diabetes. Although we used longitudinal data to compute CKD remission rates,
persistence and/or regression of albuminuria can be easily obtained in subsets of cross sec-
tional populations with repeated ACR and eGFR measurements, as has been done for the
NHANES population [27]. The present study adds to the body of evidence indicating that the
current incidence model is rigorous across populations and chronic diseases outcomes and
may be used to estimate incidence density of CKD when longitudinal follow-up is not feasible,
but serial cross-sectional data are available.
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